A launch planning team for a new metabolic treatment faced a big question:
How can we forecast the drug’s market potential when we aren’t able to accurately size the patient population with current data?
The team knew the market opportunity was significant, but faced several barriers to getting an accurate forecast:
Having assessed the challenges, the team realized that a traditional, single-data-source approach would not yield satisfactory results for this drug and niche population.
Integrated market sizing to build a previously undefined patient segment
The launch team partnered with Clarivate to determine the right approach and data sets that would give them a confident market size.
PHASE 1:Approach alignment
Clarivate assembled a team of market consultants, epidemiology experts, and data scientists, bringing primary market research and methodology inputs, as well as a deep knowledge of the disease and landscape.
The team brainstormed the pros and cons of several potential approaches before landing on an integrated epidemiology and claims analysis which they deduced would provide the most realistic population size.
PHASE 2: Data extraction and analysis
PHASE 3: Market size definition and recommendations
Clarivate provided the launch team with the validated market size and key insights to address their business questions.
In addition, Clarivate walked the team through the nuances of the analyses and provided future recommendations on how to best to track this
population moving forward.
With far greater confidence in their market size projections, the client was empowered to make better decisions around:
Looking for more accurate market sizing?
When you are faced with tough business questions, Clarivate analytics specialists are here to help you define the best path forward.